Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...
Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...
Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...
As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...
By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...
Major U.S. equities indexes rose Monday afternoon amid optimism Congress could soon agree on a spending plan to end the ...
Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech ...
In the run-up to the 2020 election, all 20 Democratic presidential candidates promised voters they’d pursue bold changes to ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...
Money Talks News on MSN
Pfizer's 2025 COVID vaccine boosts immunity 4x, access severely limited nationwide
Pfizer's new COVID vaccine shows promising results with 4x immunity boost, but Kennedy's restrictions leave most Americans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback